UNITY Anti-Aging Drug Research and Development Made Significant Progress Partner Asasin Pharmaceuticals Received Milestone Payment

UNITY's clinical trial is an open Phase I clinical study designed to assess the safety, toerability and pharmacodynamics of UBX1325 in patients with advanced DMEs.
the pilot program to include about 15 patients and is expected to obtain safety and tolerance data in the first half of 2021.
, according to public information released by UNITY, the drug showed significant ability to affect senescical cells, reduce blood vessel leakage, and improve retinal function in preclinical trials.
Aceh Pharmaceuticals reached a strategic partnership with UNITY in 2016, which includes a cooperation agreement on compound libraries, and UNITY is authorized to screen assante Pharmaceuticals' Bcl-2 series of compounds for development in the field of anti-aging.
BM-962 was selected by UNITY as a compound for research and development of UBX1325, and the cooperation was carried out in accordance with the terms of the agreement between the parties.
, which owns the compound's Greater China interests, plans to form a joint venture with UNITY to jointly develop the Chinese market.
note: There are deletions in the original text